Delivery Order SPE2DB24D2100-SPE2DB25FBGGU
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,595.40 to AmerisourceBergen Drug Corp for the supply of Activase 100 mg vials, with an ultimate completion date of September 12, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,875.45 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed-price contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive, non-set-aside award. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $20,455.11 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Activase 50 mg vials, with an ultimate completion date of August 15, 2025. This is a firm fixed-price, non-set-aside contract issued to the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials, with a ceiling value of $17,807.88. This firm fixed-price contract was competitively awarded without set-aside designation and has an ultimate completion date of August 1, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $21,231.29 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 14, 2025. AmerisourceBergen Drug Corp will perform the work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $22,365.75 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed price contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award was made through competitive procurement with no set-aside designation. Performance will take place at...
- The Defense Logistics Agency awarded a $35.5K firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Activase 100 mg vials, with completion scheduled for September 10, 2025. The contract is unclassified as a set-aside and represents a competitively awarded delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Department's Medical Supply Chain awarded a delivery order valued at $11,730.80 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. The contract, issued on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a firm fixed-price procurement with no set-aside designation. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $36,187.73 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Activase, a thrombolytic medication used in acute medical treatment. This competitively awarded, firm fixed-price contract was issued on September 9, 2025, with an ultimate completion date of September 10, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for 50 mg vials of Activase on August 20, 2025, with a contract ceiling value of $3,662.41. This firm fixed-price delivery order, which carries an ultimate completion date of August 21, 2025, represents a competitively awarded non-set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is executed under AmerisourceBergen Drug Corp's larger...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGGUDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,676.32 to AmerisourceBergen Drug Corp for the supply of Activase 100 mg vials, with an ultimate completion date of September 12, 2025. This firm fixed-price, non-set-aside contract was awarded competitively on September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive prime vendor contract enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including critical medications, vaccines, and medical devices across multiple therapeutic domains. The company's award history demonstrates consistent capability in fulfilling federal procurement requirements through open competition, with delivery orders ranging substantially in value and supporting Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.7k | 9/11/25 |